<DOC>
	<DOCNO>NCT02756013</DOCNO>
	<brief_summary>The purpose study evaluate side effect effectiveness give standard paclitaxel chemotherapy dos base actual body surface area combination standard dose carboplatin chemotherapy overweight woman .</brief_summary>
	<brief_title>Weight-based Dosing Dense Weekly Paclitaxel Carboplatin Overweight Patients w/ BSA &gt; 2.0</brief_title>
	<detailed_description>Primary Objective The primary objective prospectively evaluate Relative Dose Intensity ( RDI ) toxicity weight-based dose dense weekly paclitaxel carboplatin overweight patient BSA &gt; 2.0 compare Japanese Gynecologic Oncology Group trial ( JGOG 2016 ) 6 - 9 cycle chemotherapy . Secondary Objective ( ) The secondary objective evaluate progression-free survival patient population . Study Design This descriptive study determine relative dose intensity patient overweight BSA great 2.0 achieve .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients histologically confirm presumed diagnosis gynecologic malignancy chemotherapy paclitaxel carboplatin plan . Body Surface area &gt; 2.0 Patients must adequate : Renal function : Creatinine &lt; 1.5 x Institutional upper limit normal ( ULN ) Bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1,500/mcl . This ANC induce support granulocyte colony stimulate factor . Platelets ≥ 100,000/mcl . Hepatic function : Bilirubin ≤ 1.5 x ULN . Aspartate aminotransferase ( AST ) ( SGOT ) ≤ 2.5 x ULN . Alkaline phosphatase ≤ 2.5 x ULN . Neurologic function : Neuropathy ( sensory motor ) ≤ CTCAE Grade 1 . Patients must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 . Patients must enter within 12 week diagnosis . Subjects must ability understand willingness sign write informed consent document . Patients receive prior radiotherapy portion abdominal cavity pelvis . Prior radiation localize cancer breast , head neck , skin permit , provide complete three year prior registration , patient remain free recurrent metastatic disease . Patients receive prior chemotherapy . Patients acute hepatitis active infection require parenteral antibiotic . Patients clinically significant cardiovascular disease . This include : Myocardial infarction unstable angina &lt; 6 month prior registration . New York Heart Association ( NYHA ) Grade II great congestive heart failure Serious cardiac arrhythmia require medication . This include asymptomatic , atrial fibrillation control ventricular rate . Patients pregnant nursing . Patients medical history condition otherwise previously specify opinion investigator exclude participation study . Patients know allergy cremophor polysorbate 80 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>chemotherapy dosing</keyword>
	<keyword>Body surface area</keyword>
	<keyword>BSA</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>dose dense</keyword>
</DOC>